Salivary Alpha-amylase Enzyme and Salivary Cortisol Level in Depression after Treatment with Fluoxetine

Hypothalamic-Pituitary-Adrenal (HPA) axis and its end product cortisol have been extensively investigated in patients with depressive disorders for many years. Recently, salivary alpha-amylase (sAA) had emerged as a new biomarker non-invasive more convenience protocol measuring sympathetic activity which were also associated depression. Selective Serotonin Reuptake Inhibitor (SSRI) is antidepressant drug used to treat The aim of this study was determine whether decrease sAA levels could be observed subjects depression who treated by fluoxetine. total 25 depressed 10 healthy controls. examined before therapy, after 2, 4 6 weeks fluoxetine administration using portable cocorometer. Salivary Elisa method. therapeutic effect assessed Hamilton Depression Rating Scale (HDRS). Results: level significantly decreased (p<0.001) followed at least 50% reduction HDRS scores administration. Levels higher the group than control. Conclusions: Measurement can potential response addition cortisol.